Judgment

Agribusiness investment firm Packhorse Pastoral has lost an appeal bid in a row with placement agent Burgoyne Capital, after its $120 million portfolio of cattle stations was put up for sale following the death of a co-founder.

Raysons Constructions has successfully appealed a NSW Civil and Administrative Tribunal decision in a fight with a Sydney owners corporation over major defects at an apartment complex in Meadowbank.

A judge has allowed a prison inmate in Victoria to file a class action over alleged price gouging for products sold in the prison shop, but warned it was unlikely that he will be able to represent the 400 proposed group members.

The private credit firm that backed bankrupt publican Jon Adgemis has failed in its fight for the costs of its court action against the corporate regulato over notices to produce documents it said were shielded by legal professional privilege. 

FX Group Holdings has partly succeeded in its appeal of a finding that it owes private equity firm CPE Capital $96.89 million in a dispute over a profit-sharing agreement tied to the sale of CPE’s stake in trading platform Pepperstone.

A Sydney-based spice wholesaler has lost its bid to register a trade mark containing the word 'Tadka', with a delegate finding the word describes an Indian cooking technique.

In reasons for siding with a Regis Resources unit, a judge has found former environment minister Tanya Plibersek lacked authority to declare part of the McPhillamys gold mine heritage protected after she received new information about a "central and material" Dreaming story. 

The High Court of New Zealand has refused to grant New Zealand Rugby an interim injunction preventing the Australian Rugby League Commission from using the names 'PNG Chiefs' or 'Chiefs' in New Zealand.

The owners corporation at a mixed use development on the lower north shore of Sydney has lost an appeal seeking work orders against builder Ceerose and developer Zone Q, after partially winning its initial case.

An appeals court has found US drug maker Cosette could not rely on sales performance figures to justify its termination of a $672 million merger agreement with Mayne Pharma Group.